Market capitalization | $637.17m |
Enterprise Value | $495.77m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 28.56 |
P/S ratio (TTM) P/S ratio | 36.70 |
P/B ratio (TTM) P/B ratio | 4.99 |
Revenue growth (TTM) Revenue growth | -35.96% |
Revenue (TTM) Revenue | $17.36m |
As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.
8 Analysts have issued a Capricor Therapeutics, Inc. forecast:
8 Analysts have issued a Capricor Therapeutics, Inc. forecast:
Mar '25 |
+/-
%
|
||
Revenue | 17 17 |
36%
36%
|
|
Gross Profit | - - |
-
|
|
EBITDA | -57 -57 |
128%
128%
|
EBIT (Operating Income) EBIT | -57 -57 |
119%
119%
|
Net Profit | -55 -55 |
126%
126%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps. The company was founded in August 2005 and is headquartered in Beverly Hills, CA.
Head office | United States |
CEO | Linda Marbán |
Employees | 160 |
Founded | 1996 |
Website | capricor.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.